Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.

Chen Z, Diaz G, Pollicino T, Zhao H, Engle RE, Schuck P, Shen CH, Zamboni F, Long Z, Kabat J, De Battista D, Bock KW, Moore IN, Wollenberg K, Soto C, Govindarajan S, Kwong PD, Kleiner DE, Purcell RH, Farci P.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11369-E11378. doi: 10.1073/pnas.1809028115. Epub 2018 Nov 12.

2.

Current and Future Management of Chronic Hepatitis D.

Farci P, Anna Niro G.

Gastroenterol Hepatol (N Y). 2018 Jun;14(6):342-351.

3.

Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma.

Diaz G, Engle RE, Tice A, Melis M, Montenegro S, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Bock KW, Moore IN, Zamboni F, Govindarajan S, Kleiner DE, Farci P.

Mol Cancer Res. 2018 Sep;16(9):1406-1419. doi: 10.1158/1541-7786.MCR-18-0012. Epub 2018 Jun 1.

PMID:
29858376
4.

Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.

Sekhar V, Pollicino T, Diaz G, Engle RE, Alayli F, Melis M, Kabat J, Tice A, Pomerenke A, Altan-Bonnet N, Zamboni F, Lusso P, Emerson SU, Farci P.

PLoS Pathog. 2018 Mar 14;14(3):e1006916. doi: 10.1371/journal.ppat.1006916. eCollection 2018 Mar.

5.

Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway.

Chen J, Zaidi S, Rao S, Chen JS, Phan L, Farci P, Su X, Shetty K, White J, Zamboni F, Wu X, Rashid A, Pattabiraman N, Mazumder R, Horvath A, Wu RC, Li S, Xiao C, Deng CX, Wheeler DA, Mishra B, Akbani R, Mishra L.

Gastroenterology. 2018 Jan;154(1):195-210. doi: 10.1053/j.gastro.2017.09.007. Epub 2017 Sep 15.

6.

Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia.

Clemente MG, Frau F, Bernasconi M, Macis MD, Cicotto L, Pilleri G, De Virgiliis S, Castiglia P, Farci P.

United European Gastroenterol J. 2017 Jun;5(4):527-531. doi: 10.1177/2050640616665030. Epub 2016 Aug 9.

7.

Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability.

Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong LN, Katz LH, Shetty K, Rashid A, Su X, White J, Li L, Wang AY, Blechacz B, Raju GS, Davila M, Nguyen BN, Stroehlein JR, Chen J, Kim SS, Levin H, Machida K, Tsukamoto H, Michaely P, Tzatsos A, Mishra B, Amdur R, Mishra L.

Hepatology. 2017 Feb;65(2):678-693. doi: 10.1002/hep.28927. Epub 2016 Dec 24.

8.

Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology.

Zhang Q, Matsuura K, Kleiner DE, Zamboni F, Alter HJ, Farci P.

J Transl Med. 2016 Nov 28;14(1):328.

9.

Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection.

Raghwani J, Rose R, Sheridan I, Lemey P, Suchard MA, Santantonio T, Farci P, Klenerman P, Pybus OG.

PLoS Pathog. 2016 Sep 15;12(9):e1005894. doi: 10.1371/journal.ppat.1005894. eCollection 2016 Sep.

10.

Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.

Matsuura K, De Giorgi V, Schechterly C, Wang RY, Farci P, Tanaka Y, Alter HJ.

Hepatology. 2016 Sep;64(3):732-45. doi: 10.1002/hep.28660. Epub 2016 Jul 7.

11.

Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue.

Harouaka D, Engle RE, Wollenberg K, Diaz G, Tice AB, Zamboni F, Govindarajan S, Alter H, Kleiner DE, Farci P.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1375-80. doi: 10.1073/pnas.1516879113. Epub 2016 Jan 19.

12.

Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.

Briguglio I, Loddo R, Laurini E, Fermeglia M, Piras S, Corona P, Giunchedi P, Gavini E, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P, Pricl S, Carta A.

Eur J Med Chem. 2015 Nov 13;105:63-79. doi: 10.1016/j.ejmech.2015.10.002. Epub 2015 Oct 9.

PMID:
26479028
13.

Integrated ordination of miRNA and mRNA expression profiles.

Diaz G, Zamboni F, Tice A, Farci P.

BMC Genomics. 2015 Oct 12;16:767. doi: 10.1186/s12864-015-1971-9.

14.

Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.

Zhu R, Baker SS, Moylan CA, Abdelmalek MF, Guy CD, Zamboni F, Wu D, Lin W, Liu W, Baker RD, Govindarajan S, Cao Z, Farci P, Diehl AM, Zhu L.

J Pathol. 2016 Mar;238(4):531-42. doi: 10.1002/path.4650. Epub 2016 Jan 29.

PMID:
26415102
15.

Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge.

Bukh J, Engle RE, Faulk K, Wang RY, Farci P, Alter HJ, Purcell RH.

J Virol. 2015 Sep;89(17):9128-32. doi: 10.1128/JVI.01194-15. Epub 2015 Jun 17.

16.

Antiviral properties from plants of the Mediterranean flora.

Sanna G, Farci P, Busonera B, Murgia G, La Colla P, Giliberti G.

Nat Prod Res. 2015;29(22):2065-70. doi: 10.1080/14786419.2014.1003187. Epub 2015 Jan 23.

PMID:
25613403
17.

Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma.

Melis M, Diaz G, Kleiner DE, Zamboni F, Kabat J, Lai J, Mogavero G, Tice A, Engle RE, Becker S, Brown CR, Hanson JC, Rodriguez-Canales J, Emmert-Buck M, Govindarajan S, Kew M, Farci P.

J Transl Med. 2014 Aug 21;12:230. doi: 10.1186/s12967-014-0230-1.

18.

Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.

Tonelli M, Novelli F, Tasso B, Vazzana I, Sparatore A, Boido V, Sparatore F, La Colla P, Sanna G, Giliberti G, Busonera B, Farci P, Ibba C, Loddo R.

Bioorg Med Chem. 2014 Sep 1;22(17):4893-909. doi: 10.1016/j.bmc.2014.06.043. Epub 2014 Jul 1.

PMID:
25082514
19.

Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.

Loddo R, Briguglio I, Corona P, Piras S, Loriga M, Paglietti G, Carta A, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P.

Eur J Med Chem. 2014 Sep 12;84:8-16. doi: 10.1016/j.ejmech.2014.07.011. Epub 2014 Jul 4.

PMID:
25014745
20.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
21.

Natural history of hepatitis C in thalassemia major: a long-term prospective study.

Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, Corrias C, Farci P, Congiu G, Galanello R.

Eur J Haematol. 2013 Jun;90(6):501-7. doi: 10.1111/ejh.12086. Epub 2013 Mar 14.

PMID:
23414443
22.

Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F, Farci P.

Int J Cancer. 2013 Aug 15;133(4):816-24. doi: 10.1002/ijc.28075. Epub 2013 Mar 16.

23.

Liver regeneration signature in hepatitis B virus (HBV)-associated acute liver failure identified by gene expression profiling.

Nissim O, Melis M, Diaz G, Kleiner DE, Tice A, Fantola G, Zamboni F, Mishra L, Farci P.

PLoS One. 2012;7(11):e49611. doi: 10.1371/journal.pone.0049611. Epub 2012 Nov 21.

24.

Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure.

Wu W, Chen Z, Cheng N, Watts NR, Stahl SJ, Farci P, Purcell RH, Wingfield PT, Steven AC.

J Struct Biol. 2013 Jan;181(1):53-60. doi: 10.1016/j.jsb.2012.10.004. Epub 2012 Oct 16.

25.

Clinical features of hepatitis D.

Farci P, Niro GA.

Semin Liver Dis. 2012 Aug;32(3):228-36. doi: 10.1055/s-0032-1323628. Epub 2012 Aug 29. Review.

PMID:
22932971
26.

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group.

Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2.

PMID:
22859496
27.

Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Farci P, Wollenberg K, Diaz G, Engle RE, Lai ME, Klenerman P, Purcell RH, Pybus OG, Alter HJ.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14562-7. doi: 10.1073/pnas.1210592109. Epub 2012 Jul 24.

28.

Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma.

Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L.

Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):530-8. doi: 10.1038/nrgastro.2012.114. Epub 2012 Jun 19. Review.

29.

Association of chronic hepatitis C with recurrent brief depression.

Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P.

J Affect Disord. 2012 Dec 10;141(2-3):361-6. doi: 10.1016/j.jad.2012.03.020. Epub 2012 May 18.

PMID:
22609196
30.

5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4.

Vitale G, Corona P, Loriga M, Carta A, Paglietti G, Giliberti G, Sanna G, Farci P, Marongiu ME, La Colla P.

Eur J Med Chem. 2012 Jul;53:83-97. doi: 10.1016/j.ejmech.2012.03.038. Epub 2012 Mar 30.

PMID:
22513121
31.

Cytotoxic phloroglucinols from the leaves of Myrtus communis.

Cottiglia F, Casu L, Leonti M, Caboni P, Floris C, Busonera B, Farci P, Ouhtit A, Sanna G.

J Nat Prod. 2012 Feb 24;75(2):225-9. doi: 10.1021/np2009219. Epub 2012 Jan 25.

PMID:
22276775
32.

New insights into the HCV quasispecies and compartmentalization.

Farci P.

Semin Liver Dis. 2011 Nov;31(4):356-74. doi: 10.1055/s-0031-1297925. Epub 2011 Dec 21. Review.

PMID:
22189976
33.

Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively.

Meunier JC, Bukh J, Diaz G, Tovo PA, Casadei AM, Quinti I, Iorio R, Emerson S, Purcell RH, Farci P.

J Infect Dis. 2011 Dec 1;204(11):1741-5. doi: 10.1093/infdis/jir631. Epub 2011 Oct 17.

34.

Acridine derivatives as anti-BVDV agents.

Tonelli M, Vettoretti G, Tasso B, Novelli F, Boido V, Sparatore F, Busonera B, Ouhtit A, Farci P, Blois S, Giliberti G, La Colla P.

Antiviral Res. 2011 Aug;91(2):133-41. doi: 10.1016/j.antiviral.2011.05.005. Epub 2011 May 14.

PMID:
21619897
35.

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.

Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9. doi: 10.1016/j.bcmd.2010.05.005. Epub 2010 Jun 17.

PMID:
20678715
36.

B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure.

Farci P, Diaz G, Chen Z, Govindarajan S, Tice A, Agulto L, Pittaluga S, Boon D, Yu C, Engle RE, Haas M, Simon R, Purcell RH, Zamboni F.

Proc Natl Acad Sci U S A. 2010 May 11;107(19):8766-71. doi: 10.1073/pnas.1003854107. Epub 2010 Apr 26.

37.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
38.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group.

Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4. doi: 10.1053/j.gastro.2009.03.006. Epub 2009 Mar 19.

PMID:
19303414
39.

Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.

Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, Piratvisuth T, Farci P, Chow WC, Jia JD, Paik W, Wintfeld N, Pluck N.

Liver Int. 2008 Apr;28(4):477-85. doi: 10.1111/j.1478-3231.2008.01696.x.

PMID:
18339074
40.

The use of molecular assays in the management of viral hepatitis.

Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, Farci P, Lampertico P, Marzano A, Niro G, Pisani G, Prati D, Puoti M, Raimondo G, Santantonio T, Smedile A, Lauria F; Italian Association for the Study of the Liver (AISF).

Dig Liver Dis. 2008 Jun;40(6):395-404. doi: 10.1016/j.dld.2007.12.016. Epub 2008 Mar 5.

PMID:
18321798
41.

Treatment of chronic hepatitis D.

Farci P, Chessa L, Balestrieri C, Serra G, Lai ME.

J Viral Hepat. 2007 Nov;14 Suppl 1:58-63. Review.

PMID:
17958644
42.

Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy.

Carta MG, Hardoy MC, Garofalo A, Pisano E, Nonnoi V, Intilla G, Serra G, Balestrieri C, Chessa L, Cauli C, Lai ME, Farci P.

Clin Pract Epidemiol Ment Health. 2007 Oct 23;3:22.

43.

In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, Farci P, Emerson SU, Chisari FV, Purcell RH, Bukh J.

J Virol. 2007 Jul;81(13):7208-19. Epub 2007 Apr 4.

44.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.

Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Gut. 2007 May;56(5):699-705. Epub 2006 Nov 24.

45.

Treatment of chronic hepatitis D: New advances, old challenges.

Farci P.

Hepatology. 2006 Sep;44(3):536-9. No abstract available.

PMID:
16941704
46.
47.

Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.

Cauli C, Serra G, Chessa L, Balestrieri C, Scioscia R, Lai ME, Farci P.

Haematologica. 2006 Jun;91(6 Suppl):ECR26.

48.

Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively.

Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, Coiana A, Cao D, Casadei AM, Ledda R, Iorio R, Vegnente A, Diaz G, Tovo PA.

Proc Natl Acad Sci U S A. 2006 May 30;103(22):8475-80. Epub 2006 May 17.

49.

Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?

Balestrieri C, Serra G, Cauli C, Chessa L, Balestrieri A, Farci P.

Blood. 2006 Apr 15;107(8):3409-10. No abstract available.

50.

Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.

Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, Farci P, O'Brien CB, Lardelli P, Blotner S, Zeuzem S.

J Hepatol. 2006 Apr;44(4):679-85. Epub 2006 Jan 25.

PMID:
16487620

Supplemental Content

Support Center